



Published in final edited form as:

Parasitology. 2018 November ; 145(13): 1739–1747. doi:10.1017/S0031182018000811.

Whole genome amplification and exome sequencing of archived schistosome miracidia

Winka Le Clec'h¹, Frédéric D. Chevalier¹, Marina McDew-White¹, Fiona Allan², Bonnie L. Webster², Anouk N. Gouvras², Safari Kinunghi³, Louis-Albert Tchuem Tchuente^{4,5}, Amadou Garba⁶, Khalfan A. Mohammed⁷, Shaali M. Ame⁸, Joanne P. Webster⁹, David Rollinson², Aidan M. Emery², and Timothy J. C. Anderson¹

¹Texas Biomedical Research Institute, Department of Genetics, PO Box 760549, San Antonio, TX 78245-0549, USA

²The Natural History Museum, Department of Life Sciences, Cromwell Road, London SW7 5BD, United Kingdom

³National Institute for Medical Research, Mwanza Research Centre, Mwanza, United Republic of Tanzania

⁴Laboratoire de Parasitologie et Ecologie, Université de Yaoundé I, Yaoundé, Cameroon

⁵Center for Schistosomiasis & Parasitology, P.O. Box 7244, Yaoundé, Cameroon

⁶Réseau International Schistosomoses, Environnement, Aménagement et Lutte (RISEAL-Niger), 333, Avenue des Zarmakoye, B.P. 13724, Niamey, Niger

⁷Helminth Control Laboratory Unguja, Ministry of Health, Zanzibar, United Republic of Tanzania

⁸Public Health Laboratory - Ivo de Carneri, Pemba, United Republic of Tanzania

⁹Centre for Emerging, Endemic and Exotic Diseases, Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London, AL9 7TA, UK United Kingdom

Abstract

Adult schistosomes live in the blood vessels and cannot easily be sampled from humans, so archived miracidia larvae hatched from eggs expelled in feces or urine are commonly used for population genetic studies. Large collections of archived miracidia on FTA cards are now available through the [Schistosome Collection](#) [At the Natural History Museum \(SCAN\)](#). Here we describe protocols for whole genome amplification (WGA) of *Schistosoma mansoni* and *S. haematobium* miracidia from these cards, as well as real time PCR quantification of amplified schistosome DNA. We used microgram quantities of DNA obtained for exome capture and sequencing of single miracidia, generating dense polymorphism data across the exome. These methods will facilitate the transition from population genetics, using limited numbers of markers to population

Corresponding author: Winka Le Clec'h, Texas Biomedical Research Institute, Department of Genetics, PO Box 760549, San Antonio, TX 78245-0549, USA, winkal@txbiomed.org.

CONFLICTS OF INTEREST

None

genomics using genome-wide marker information, maximising the value of collections such as SCAN.

Keywords

Schistosoma; miracidia; FTA cards; whole genome amplification; quantitative PCR; exome sequencing

INTRODUCTION

We currently lack tools for effective genome-wide characterization of schistosomes from human populations for two main reasons. First, there is the practical problem of obtaining suitable material for genomic analyses: schistosome adults live in the blood vessels and only eggs expelled in feces (*Schistosoma mansoni* and *japonicum*) or urine (*Schistosoma haematobium*) are available from patients. Microscopic miracidium larvae ($70 \times 140 \mu\text{m}$) hatched from these eggs can be used to infect snails and the cercaria larvae produced can be used to infect laboratory rodents to recover adult worms, but this approach is cumbersome, ethically questionable, and imposes strong selection and potential bias (Gower *et al.* 2007). An alternative approach is to hatch these larvae and preserve them individually on FTA cards for genetic analysis (Gower *et al.* 2007). This approach has been widely used and has greatly improved our understanding of many aspects of schistosome population biology (Steinauer *et al.* 2010; Webster *et al.* 2012; Gower *et al.* 2013, 2017). However, these studies can be severely constrained by the minute amount of DNA and therefore the relatively small number of genetic markers that can be successfully multiplexed, PCR amplified and analysed from a single miracidium. Typically these studies utilize just 8–20 microsatellite markers (Gower *et al.* 2011, 2013, 2017; Glenn *et al.* 2013; Steinauer *et al.* 2013; Aemero *et al.* 2015; Webster *et al.* 2015) or 1–3 gene regions (Van den Broeck *et al.* 2015; Li *et al.* 2017). The use of FTA cards has allowed the creation of large archived collections of FTA-preserved miracidia maintained at the Schistosome Collection at the Natural History Museum (SCAN) (Emery *et al.* 2012). SCAN currently houses around 300,000 miracidia collected from over 7,000 people from 14 countries, sampled within the past decade, providing valuable geographical and temporal populations of samples for molecular analysis.

The size and complex architecture of schistosome genomes provides an additional obstacle. Whole genome sequences of the three principal schistosome species infecting humans (*S. mansoni*, *S. haematobium* and *S. japonicum*) are now available, but these are large (363–400 Mb), and riddled with transposable elements and repeats, which comprise 40–50% of the genome and make alignment problematic (Berriman *et al.* 2009; Zhou *et al.* 2009; Protasio *et al.* 2012; Young *et al.* 2012). The large genome size also makes whole genome sequencing from populations prohibitively expensive, even with falling sequencing costs. Furthermore, the coding regions of the genome (the exome) that are of primary interest for many analyses, measures ~15 Mb and constitutes just 4% of the total genome (Young *et al.* 2012).

Exome capture methods utilize RNA baits that hybridize with the targeted exome sequences, so they can be isolated from non-coding DNA. This approach has been widely used to

rapidly and economically sequence thousands of human exomes and identify coding variants associated with disease (Rabbani *et al.* 2014; Pehlivan *et al.* 2014; Shaw *et al.* 2017). There are several attractive features of exome sequencing for schistosome miracidia: (i) this approach is scalable to working with hundreds of individual miracidia, (ii) repetitive regions of the genome that are problematic to align are removed, (iii) contaminating sequences amplified from FTA cards (e.g. bacteria from fecal matter and water) are eliminated, and (iv) reducing the genome size from 363 Mb to 15 Mb allows sequencing to high read depth, providing robust scoring of variable sites. We have previously described an exome capture approach that we used for whole genome amplified DNA prepared from adult *S. mansoni* (Chevalier *et al.* 2014). Here we adapt this approach for single miracidia. We describe methods for (i) whole genome amplification of miracidia DNA directly from FTA cards, (ii) qPCR methods for quantifying of schistosome DNA amplified and (iii) exome capture, sample multiplexing and sequencing of amplified DNA. We apply these methods to a subset of miracidia from SCAN to demonstrate the utility of these methods. Furthermore, we describe protocols for both *S. mansoni* and *S. haematobium*, the two species responsible for more than 99% of human infections (Hotez *et al.* 2006).

MATERIALS AND METHODS

1) Ethics Statement

EU-CONTRAST specimens were collected in line with project ethical approval granted by ethical committees of the Ministry of Health Dakar, Senegal, the Niger National Ethical Committee, Comité National d'Ethique, Cameroon. For specimens from the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), ethical approvals were granted by Royal Veterinary College 2015 1327; Imperial College Research Ethics Committee and SCI Ethical approval (EC no: 03.36. R&D no: 03/SB/033E); the National Institute for Medical Research (NIMR, reference no. NIMR/HQ/R.8a/Vol. IX/1022); Zanzibar Medical Research Ethics Committee in Stonetown, Zanzibar (ZAMREC, reference no. ZAMREC 0003/Sept/011); University of Georgia Institutional Review Boards, Athens, GA (2011-10353-1); Niger Republic National Consulate (reference no. 012/2010/CCNE).

All local requirements were met, including obtaining written informed consent from adults (including parents/legal guardians of children included in the studies) and followed by obtaining the assent from children included. Following sampling, a praziquantel treatment (40mg/Kg) was offered to infected participants.

2) Field collection sites

S. mansoni miracidia were collected as part of EU-CONTRAST activities from individual patients in three different West African countries in 2007: 27 patients from 2 locations in Senegal, 17 patients from 2 locations in Niger and 6 patients from 1 location in Cameroon (Supp. File 1) (Gower *et al.* 2011; Webster *et al.* 2013). Additionally, *S. mansoni* miracidia were collected as part of the SCORE programme from 64 children in 7 villages on the shores of Lake Victoria in Tanzania (East Africa) in January 2012 (Ezeamama *et al.* 2016) (Supp. File 1).

S. haematobium miracidia were collected through the SCORE Zanzibar Elimination of Schistosomiasis Transmission (ZEST) activities in 2011 from 80 children in 26 locations of the Zanzibar archipelago (East Africa) and in 2013 from 57 patients in 10 locations of Niger (West Africa) (Supp. File1).

All samples were transferred to SCAN for checking, curation and storage either immediately (SCORE), or at the close of the project (EU-CONTRAST).

3) Collection of miracidia

Our methods for recovery of *S. mansoni* eggs followed Visser and Pitchford (1972) and Gower *et al.* (2013) with some minor differences. In brief, (i) each *S. mansoni* infected stool sample (approximately 2 g) was homogenised with a plastic spatula through a 212 µm wire mesh sieve (Endecotts Ltd, UK) and washed through with approximately 1 L of locally available bottled water, (ii) the tray contents were transferred to the inner nylon mesh (200 µm pore size) of a Pitchford funnel assembly (Visser and Pitchford, 1972), washed with additional water (up to an additional 1 L), and the inner mesh removed from the assembly, (iii) the washed, filtered homogenate was drained into a 100 × 15 mm Petri dish (BD Biosciences, Belgium) by opening the tap at the base of the Pitchford funnel. The Petri dish containing the homogenate was then left in bright ambient light (not direct sunlight) to allow hatching of miracidia.

S. haematobium eggs were concentrated from each infected urine by sedimentation, then rinsed in bottled mineral water before transfer into a clean Petri dish containing mineral water and exposed to light to facilitate hatching (Webster *et al.* 2012).

Both miracidia from *S. mansoni* and *S. haematobium* were captured individually, under a binocular microscope, in 3 µL of water and spotted onto an indicating Whatman FTA Classic Indicating card (GE Healthcare Life Sciences, UK) using a 20 µL micropipette. Spotted samples (up to approximately 80 per card) can be easily located on the cards because the pink dye turns white after water contact. The cards were then allowed to dry for 1 hour at room temperature before being stored in a sealed plastic bag and then shipped to UK, ultimately to be stored in the SCAN repository.

4) Preparation of FTA samples for whole genome amplification (WGA)

For each sample prepared, a 2 mm diameter disc was removed from the centre of the dye-cleared area using a 2 mm Harris Micro-punch (GE Healthcare Life Sciences, UK). This 2 mm disc corresponds to the entire spot containing the whole miracidium. Each punch was placed individually in 500 µL Matrix screw cap 2D barcode storage tubes (Thermo Fisher Scientific, UK) and shipped to Texas Biomedical Research Institute for further preparation.

The punches were individually transferred into 1.5 mL sterile microtubes using sterile tips. Punches were washed 3 times with FTA Purification Reagent (GE Healthcare Life Sciences, USA) then rinsed 2 times with TE⁻¹ buffer (10 mM Tris, 0.1 mM EDTA, pH 8). Washing and rinsing steps were performed by adding 200 µL of solution in each tube followed by 5 minutes of incubation on a nutating mixer (24 RPM) at room temperature and then discarding the solution while minimizing contact between the pipette tip and the punch.

Punches were finally dried in tubes during 10 minutes at 56°C in a dry bath incubator (Chevalier *et al.* 2016).

5) Whole genome amplification (WGA)

We conducted WGA on 1 to 4 miracidia from each patient from all the sites sampled until a positive WGA was obtained. We performed WGA on each punch using the Illustra GenomiPhi V2 DNA Amplification kit (GE Healthcare Life Sciences, USA). Punches were transferred into 0.2 mL sterile tubes using a sterile tip. Reactions were performed following the manufacturer's instructions, immersing each punch in 9 µL of sample buffer and keeping tubes on ice after the denaturation step (3 minutes at 95°C) while adding a mix of 9 µL of reaction buffer and 1 µL of Phi29 polymerase. After the amplification step (2h30 at 30°C and 10 minutes at 65°C), we added 130 µL of sterile water into the reaction tube and purified the 150 µL of amplified genome with the SigmaSpin™ Sequencing reaction Clean-up (Sigma-Aldrich, USA), following the manufacturer protocol. We quantified purified samples using the Qubit dsDNA BR assay (Invitrogen, USA).

6) Real time quantitative PCR on schistosome WGA samples

We performed real time quantitative PCR (qPCR) reactions to estimate the proportion of schistosome genome in each WGA sample. This was done because FTA samples can contain contaminant DNA, such as human or bacterial DNA, which is co-amplified with schistosome DNA during the WGA step. In this assay, we amplified the *S. mansoni* α -tubulin 1 (*sat-1*) gene, which is present in low copy (gene number: Smp_090120; accession number: M80214) (Webster *et al.* 1992) or the putative *S. haematobium* α -tubulin 2. The latter was identified by performing a blastn (v2.2.29) using the *S. mansoni* α -tubulin (Duvaux-Miret *et al.* 1991; accession number: S79195) against the *S. haematobium* reference genome (SchHae_1.0; assembly accession number: GCA_000699445.1). Reactions were performed in duplicate using the AB1 prism 7900HT Sequence Detection system (Applied Biosystems) as follows: 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Duplicate reactions showing a difference in C_T greater than one were rerun. We examined the melting curve (60°C to 95°C) at the end of each assay to verify the uniqueness of the PCR products generated. The reaction mixture consisted of 5 µL of SYBR Green MasterMix (Applied Biosystems), 0.3 µL of 10 µM forward primer (*S. mansoni*: CGAAATTGGAGTTTGCTGTGT; *S. haematobium*: GGTGGTACTGGTCTGGTTT) and 10 µM reverse primer (*S. mansoni*: TGTAGGTTGGACGCTCTATATC; *S. haematobium*: AAAGCACAATCCGAATGTTCTAA) amplifying 229 bp of the *sat-1* gene for *S. mansoni* and 178 bp of the α -tubulin 2 for *S. haematobium*, 3.4 µL of sterile water and 1 µL of total DNA template (normalized at 20 ng. µL⁻¹). We plotted standard curves using seven dilutions of a purified *sat-1* PCR product for *S. mansoni* (*sat-1* copies. µL⁻¹: 2.19×10¹, 2.19×10², 2.19×10³, 2.19×10⁴, 2.19×10⁵, 2.19×10⁶, 2.19×10⁷) or seven dilutions of a purified α -tubulin 2 PCR product for *S. haematobium* (α -tubulin 2 copies. µL⁻¹: 1.29×10¹, 1.29×10², 1.29×10³, 1.29×10⁴, 1.29×10⁵, 1.29×10⁶, 1.29×10⁷). The number of *sat-1* or α -tubulin 2 copies in each sample was estimated according to the standard curve.

7) Exome library preparation and sequencing

We captured schistosome (*S. mansoni* or *S. haematobium*) exomes using the SureSelect^{XT2} Target Enrichment System (Agilent) according to the manufacturer's protocol. For each library (i.e. each sample), we sheared 1 µg of WGA DNA by adaptive focused acoustics (Duty factor: 10%; Peak Incident Power: 175; Cycles per Burst: 200; Duration: 180 seconds) in AFA tubes, using a Covaris S220 instrument with SonoLab software version 7 (Covaris, Inc., USA), to recover fragmented DNA between 150–200 bp. We used 5 PCR cycles for the pre-capture and 8 PCR cycles for post-capture amplifications. In order to make the capture step cost efficient, we added unique indexes to each library prior to exome capture (pre-capture indexing method), pooled equal amounts of DNA from 16 libraries, and then performed the capture. A capture requiring a total of 750 ng indexed DNA, we pooled 46.875 ng of each of the 16 libraries. To minimize uneven capture of each samples, we pooled libraries from samples showing similar quantities of schistosome genomes previously estimated by qPCR. The capture was performed using sets of baits from the SureSelect^{XT} Target Enrichment System (Agilent) (120 bp RNA molecules) specific to each species.

The design of the baits used to capture the *S. mansoni* exome (SureSelect design ID: S0398493) has already been described in Chevalier *et al.* 2014. We use our experience with the *S. mansoni* bait design to improve our design strategy for *S. haematobium*. Unlike, the *S. mansoni* design, (i) we included all exons that passed the low complexity threshold (rather than only the exons to which sequences can be unambiguously aligned); (ii) we included exons from vaccine candidates (Supp. File 2); and (iii) we designed baits to ensure effective capture of *ShSULT-OR* gene (Sha_104171), a drug target of particular interest (Taylor *et al.* 2017). The design (SureSelect design ID: S0742423) was made using the latest *S. haematobium* genome version (SchHae_1.0; assembly accession number: GCA_000699445.1) and its corresponding annotation. The final set of *S. haematobium* baits included 156,004 from the nuclear genome and 67 from the mitochondrial genome. These cover 96% (62,106/64,642) of the exons and account for 94% of the exome length (15,002,706 bp/15,895,612 bp). The sequences covered by baits are referred to as the bait regions. Each captured exon was covered by 2.59 baits on average.

We sequenced the pooled barcoded exome libraries using 100 bp pair-end reads (16 samples per lane of flowcell) on HiSeq 2500 sequencer (Illumina). Raw sequence data has been submitted to the NCBI Sequence Read Archive under accession numbers SRP136210 and SRP136277.

8) Sequencing data analyses

We aligned the sequencing data against the *S. mansoni* reference genome (v5; ftp://ftp.sanger.ac.uk/pub/pathogens/Schistosoma/mansoni/genome/Assembly-v5/ARCHIVE/sma_v5.0.chr.fa.gz) or the *S. haematobium* reference genome (SchHae_1.0; assembly accession number: GCA_000699445.1) using BWA (v0.7.12) (Li and Durbin, 2009) and SAMtools (v1.2) (Li *et al.* 2009). Realignment around indels was performed using GATK (v3.3-0-g37228af) (McKenna *et al.* 2010; DePristo *et al.* 2011). PCR duplicates were marked using picard (v1.136). Q-score recalibration and variant (SNP/indel) calling by the UnifiedGenotyper module were performed using GATK. Bait representation, capture

efficiency and read depth analyses were performed using BEDTools (v2.21.0) (Quinlan and Hall, 2010). The variant calling set was filtered using VCFtools (v0.1.14) (Danecek *et al.* 2011) to retain only variants in the bait regions and with a minimum read depth of 10 and a minimum genotype quality score of 80.

9) Statistics and data representation

Statistics analyses, calculation of capture efficiency, calculation of the read depth ratio of sex-chromosome, analysis of read depth surrounding bait regions and data visualisations were performed using R (v3.3.1). Figure 1 summarizes our pipeline for generating and analysing exome sequence from single miracidia.

RESULTS

1) Whole genome amplification of single miracidia

We performed WGA on a total of 412 FTA-preserved samples. These include 101 *S. mansoni* samples from East Africa (Tanzania) and 90 *S. mansoni* samples from West Africa (Senegal, Niger and Cameroon) (1 to 3 samples per patient) as well as 138 *S. haematobium* samples from East Africa (Zanzibar archipelago) and 83 FTA preserved *S. haematobium* samples from West Africa (Niger) (1 to 4 samples per patient). This resulted in an average of 3.8 ± 0.66 μg of DNA (mean \pm s.d.) from each *S. mansoni* sample and an average of 2.8 ± 0.48 μg of DNA from each *S. haematobium* sample.

The amount of schistosome DNA per sample is critical for downstream genomic assays: samples with no schistosome DNA need to be removed, while samples with low levels (<100 copies) of schistosome template DNA result in failed exome capture. To estimate the quantity of schistosome DNA in each WGA, we quantified a low copy gene (*sat-1* for *S. mansoni* and α -tubulin 2 for *S. haematobium*) using qPCR. While DNA was successfully amplified from almost 100% of the spots (Table 1), the qPCR assay revealed that only 59.4% and 41.11% of the whole genome amplified samples were positive for *S. mansoni* from the East and West African samples respectively. For the *S. haematobium* samples 47.10% of schistosome positive WGA samples were from the East and 66.26% from the West African samples. We found no *S. mansoni* positive samples among 14 FTA punches examined from Cameroon (Table 1).

The quantity of *S. mansoni* DNA obtained from single miracidia after WGA varied over five orders of magnitude (Figure 2) among the 97 *S. mansoni* positive samples from East (n=60) and West Africa (n=37). Two samples from each region (3% of East African and 5% West African samples) contained less than 100 copies. WGA material from East African samples showed higher quantities of *S. mansoni* DNA than WGA material from West African samples (Figure 2; Wilcoxon test; $p= 1.463 \times 10^{-6}$).

We observed similar heterogeneity in schistosome DNA quantity for WGA from the 65 *S. haematobium* positive samples from East Africa while the quantity of DNA from 55 West African *S. haematobium* WGAs varied by only three orders of magnitude, with no outliers. Only 11% (7/65) of *S. haematobium* positive samples, all from East Africa, showed less than

100 copies. We found a marginally higher quantity of *S. haematobium* DNA in West compared with East African samples (Figure 2; Wilcoxon test; $p=0.017$).

WGA from *S. haematobium* samples contained more schistosome DNA than from *S. mansoni* samples in both East (Figure 2; Wilcoxon test; $p=1.980\times 10^{-7}$) and West African samples (Figure 2; Wilcoxon test; $p=2.472\times 10^{-15}$).

2) Exome sequencing of single miracidia

We show exome sequencing data from 8 *S. mansoni* miracidia from a single Tanzanian village (Kigongo, Supp. File 1) and from 8 *S. haematobium* miracidia from 3 villages on Pemba island (Zanzibar archipelago: Chambani, Ngwachani and Chanjamjamiri; Supp. File 1). We observed efficient exome capture and sequencing for both species (Table 2). Sequencing of the exome capture libraries generated from 6 million to 26 million reads for *S. mansoni* and from 5 million to 18 million reads for *S. haematobium* (Table 2). A very high proportion of these reads were mapped to their respective genomes (95.5% and 95% on average, respectively) with only one sample from each species showing less than 90% of mapped reads (84% and 89%, respectively). The remaining DNA sequences, which were not mappable, could either be highly divergent schistosome sequences or more likely human or microbial contaminants present in the WGA sample and captured with the schistosome DNA.

We captured more than 99% of the bait regions and this was consistent across all 8 libraries of each species (Table 2). We obtained an average of 51.74 mean (30.62 median) read depth in the bait regions for the *S. mansoni* libraries and an average of 38.07 mean (30.62 median) read depth for the *S. haematobium* libraries (Table 2). Read depth was even across the exome (Figure 3), except in parts of the Z chromosome in *S. mansoni* females where read depth is halved (females are ZW). These genome regions (position 3.5–19.5 Mb and 23.5–31 Mb for *S. mansoni* (Lepesant *et al.* 2012)) correspond to the non-recombining heterochromatin domain of the W chromosome. The read depth in the Z-linked region allows us to determine the parasite sex *in silico* using a read depth ratio between the Z-linked region and the rest of the chromosome. Among the samples present in Table 2, we obtained an equal sex ratio. The *S. haematobium* genome assembly is poorly resolved and the Z-linked region still remains undefined (Table 2, Figure 3).

We also captured genome regions outside the bait regions, as shown previously (Chevalier *et al.* 2014). The read depth declines with distance from the bait regions as expected (Table 2). When we included data up to 250 bp around the bait regions, the mean and the median read depth reached ~72% and ~37% of the initial bait regions, respectively. These observations were similar for both *S. mansoni* and *S. haematobium*. Therefore our exome capture provides adequate sequence read depths for at least 250 bp surrounding bait regions allowing us to obtain information regarding adjacent genome regions containing promoters, transcription binding sites and other features of interest.

We were able to robustly identify variable sites in the exome capture libraries from each species (Table 3). The raw variant calling revealed more variable sites in *S. mansoni* than in *S. haematobium*. The raw data were further filtered using very stringent parameters

(minimum read depth of 10 and genotype quality of 80). After filtering, we retained informative sites accounting for around 74% of the initial sites identified. Among them, the vast majority (96%) were biallelic sites, less than 1% was multiallelic sites and between 3% and 4% were identified as indel sites.

DISCUSSION

1) Utility of WGA and qPCR quality check for FTA-preserved miracidia

Whole genome amplification (WGA) provides a very effective approach to generating large amounts of DNA from single miracidia for genome wide analyses (Valentim *et al.* 2009; Shortt *et al.* 2017). This approach has previously been used to generate micrograms of DNA from a *S. mansoni* laboratory genetic cross with a minimal error rate (0.45%) induced by the WGA step (Valentim *et al.* 2009). The current study extends this approach to WGA of archived miracidia collected in the field. Such material is more challenging compared to laboratory prepared miracidia because the miracidia on FTA cards may contain extensive environmental contamination, such as fecal bacteria or human DNA. Two features of the approach used are worth emphasising. First, the WGA method uses 2 mm FTA punches directly immersed in the WGA reaction, eliminating the need for initial DNA preparation. This produced around 3 µg of material which is sufficient for next generation sequencing applications that require at least 500 ng to 1 µg of DNA. Second, we developed a simple qPCR assay for quantifying amounts of *S. mansoni* and *S. haematobium* DNA present in the WGA material. This allows identification of schistosome positive samples and quantification of schistosome DNA, which is a critical step for identification of WGA samples suitable for library preparation and for grouping samples in pools with similar amounts of schistosome DNA to minimize variation in read depth.

We observed variation in the numbers of positive schistosome WGAs, ranging from 46.42% to 66.26% for *S. mansoni* or *S. haematobium* populations respectively. These results most likely reflect variations in the miracidia collection protocol (variation in egg washing, in spot sizes on FTA cards) and/or in the training of people collecting miracidia. We observed higher and more uniform concentration of *S. haematobium* DNA in WGA material, when compared with *S. mansoni* DNA (Figure 2). The higher variation in *S. mansoni* DNA amount is consistent with fecal contamination, as less contamination is expected in *S. haematobium* isolated from urine. We recommend that future miracidia collections, specifically for genomic work, should wash *S. mansoni* miracidia in clean water, prior to pipetting onto FTA cards, minimalizing contamination.

Among schistosome positive samples, we removed those showing low quantity of schistosome DNA (less than 100 copies of tubulin gene after WGA) because only higher schistosome DNA quantities gave good sequencing data.

2) Efficient exome capture from FTA preserved miracidia

Preparation of exome capture libraries using WGA material from either *S. mansoni* or *S. haematobium* led to high read depth exome sequencing data despite five orders of magnitude variation in the quantity of schistosome DNA present in the WGAs. Using very conservative

calling parameters, we scored 85,133 variable sites in *S. mansoni* and 60,193 in *S. haematobium* from just 8 individual miracidia of each species, which is equivalent to one variant every 166 bp for *S. mansoni* and every 249 bp for *S. haematobium* in the bait regions sequenced. This provides a rich source of variation for population exomic analyses and will be the focus of future studies with large numbers of samples.

Our exome capture method has several useful characteristics for working with field-collected miracidia. Exome capture effectively pulls out schistosome DNA (exons) from contaminating human or bacterial DNA so we can minimize the amount of contaminant sequence generated. Capture is very efficient and consistent (more than 99% of the expected region is captured for each sample) so we can sequence to high read depth to generate robust variant calls, or use read depth to estimate copy number. Here, for example, we can use read depth information from the *S. mansoni* Z-linked sex chromosomes for *in silico* sexing. The main disadvantages of exome sequencing are some highly variable genes may be poorly captured and many non-coding regions important for gene regulation are not captured (Biesecker *et al.* 2011), although we do effectively capture non-coding regions adjacent to bait sequences. We note that whole genome sequencing can also be done using WGA miracidia, if precautions are made to minimize contaminations during collection of miracidia.

3) Costs of exome sequencing miracidia

Exome capture methods are more expensive than other reduced representation library preparation approaches, such as RADseq (Harvey *et al.* 2016). However exome capture targets specific genome regions of interest and in a consistent manner for each sample, and shows lower levels of genotyping error and allelic drop out (Attard *et al.* 2017) than RADseq and related methods, so it has several advantages. The baits are by far the most expensive part of this method (~US\$900 for a given capture) but the pre-capture indexing method allows pooling of up to 16 samples prior the capture. This brings the capture cost down to \$56.25 per sample, while the other reagents required for library preparation are \$83.75 per sample. The overall cost per sample is therefore approximately \$140. The cost of a flow cell lane for a HiSeq 2500, sufficient to sequence 16 libraries, is currently around \$2,000 in our facility, so the final cost is \$265 per sample for an average read depth of 50. To achieve the same read depth when sequencing the entire schistosome genome requires two samples per lane, costing around \$1,000 per sample (library preparation cost is, in this case, negligible). Capturing and sequencing exomes also reduces both the analysis time and the storage capacity required for housing data because the exome represents just 4% of the complete genome (15 Mb exome vs 365 Mb genome). Exome capture is currently about fourfold less expensive than whole genome sequencing at present, ignoring the additional costs for data storage and analysis of whole genome data. The central advantage of exome capture over both RADseq and whole genome sequencing is that contaminating sequences can be effectively removed.

Our established workflow using the WGA method and qPCR quality check (Figure 1) will facilitate the transition from population genetics using a handful of loci, to population genomics using genome-wide information. Using these tools, we will be able to fully exploit

large collections of archived miracidia, such as those available through SCAN. For example, analysis of archived miracidia collected may be particularly useful for retrospective analyses of loci underlying drug resistance (Chevalier *et al.* 2016). This same approach can also be used for microscopic larval stages of other parasite species.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the help and support of our collaborator in Senegal, the late Oumar T. Diaw.

FINANCIAL SUPPORT:

Work at Texas Biomedical Research Institute (TBRI) was supported by National Institute of Allergy and Infectious Diseases Grants (R01 AI097576-01 and 5R21AI096277-01), by the National Center for Advancing Translational Sciences (CTSA/IIMS award no. UL1TR001120) and by Texas Biomedical Research Institute Forum grant (award 0467) and was conducted in facilities constructed with support from Research Facilities Improvement Program grant C06 RR013556 and RR017515 from the National Center for Research Resources of the National Institutes of Health. WL was supported by a Cowles Fellowship. CONTRAST was funded by the European Commission (FP6 STREP contract no: 032203). SCORE (<https://score.uga.edu/>) collecting activities in Tanzania and Zanzibar were funded by the University of Georgia Research Foundation Inc. (prime award no. 50816, sub awards RR374-053/4785416 and RR374-053/4893206), which is funded by the Bill & Melinda Gates Foundation for SCORE projects. SCAN is funded with support from the Wellcome Trust (grant no. 104958/Z/14/Z).

References

- Aemero M, Boissier J, Climent D, Moné H, Mouahid G, Berhe N, Erko B. Genetic diversity, multiplicity of infection and population structure of *Schistosoma mansoni* isolates from human hosts in Ethiopia. *BMC Genetics*. 2015; :16.doi: 10.1186/s12863-015-0297-6 [PubMed: 25887754]
- Attard CRM, Beheregaray LB, Möller LM. Genotyping-by-sequencing for estimating relatedness in non-model organisms: avoiding the trap of precise bias. *Molecular Ecology Resources*. 2017; doi: 10.1111/1755-0998.12739
- Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD, Aslett MA, Bartholomeu DC, Blandin G, Caffrey CR, Coghlan A, Coulson R, Day TA, Delcher A, DeMarco R, Djikeng A, Eyre T, Gamble JA, Ghedin E, Gu Y, Hertz-Fowler C, Hirai H, Hirai Y, Houston R, Ivens A, Johnston DA, Lacerda D, Macedo CD, McVeigh P, Ning Z, Oliveira G, Overington JP, Parkhill J, Perteu M, Pierce RJ, Protasio AV, Quail MA, Rajandream MA, Rogers J, Sajid M, Salzberg SL, Stanke M, Tivey AR, White O, Williams DL, Wortman J, Wu W, Zamanian M, Zerlotini A, Fraser-Liggett CM, Barrell BG, El-Sayed NM. The genome of the blood fluke *Schistosoma mansoni*. *Nature*. 2009; 460:352–358. DOI: 10.1038/nature08160 [PubMed: 19606141]
- Biesecker LG, Shianna KV, Mullikin JC. Exome sequencing: the expert view. *Genome Biology*. 2011; 12:128.doi: 10.1186/gb-2011-12-9-128 [PubMed: 21920051]
- Chevalier FD, Valentim CL, LoVerde PT, Anderson TJ. Efficient linkage mapping using exome capture and extreme QTL in schistosome parasites. *BMC Genomics*. 2014; 15:617.doi: 10.1186/1471-2164-15-617 [PubMed: 25048426]
- Chevalier FD, Le Clec'h W, Eng N, Rugel AR, de Assis RR, Oliveira G, Holloway SP, Cao X, Hart PJ, LoVerde PT, Anderson TJ. Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population. *International Journal for Parasitology*. 2016; 46:417–424. DOI: 10.1016/j.ijpara.2016.03.006 [PubMed: 27073078]
- Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, Handsaker RE, Lunter G, Marth GT, Sherry ST, McVean G, Durbin R. 1000 Genomes Project Analysis Group. The variant call format and VCFtools. *Bioinformatics*. 2011; 27:2156–2158. DOI: 10.1093/bioinformatics/btr330 [PubMed: 21653522]

- DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernysky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature Genetics*. 2011; 43:491–498. DOI: 10.1038/ng.806 [PubMed: 21478889]
- Duvaux-Miret O, Baratte B, Dissous C, Capron A. Molecular cloning and sequencing of the α -tubulin gene from *Schistosoma mansoni*. *Molecular and Biochemical Parasitology*. 1991; 49:337–340. DOI: 10.1016/0166-6851(91)90079-L [PubMed: 1775176]
- Emery AM, Allan FE, Rabone ME, Rollinson D. Schistosomiasis collection at NHM (SCAN). *Parasites & Vectors*. 2012; 5:185.doi: 10.1186/1756-3305-5-185 [PubMed: 22943137]
- Ezeamama AE, He C-L, Shen Y, Yin X-P, Binder SC, Campbell CH, Rathbun S, Whalen CC, N'Goran EK, Utzinger J, Olsen A, Magnussen P, Kinung'hi S, Fenwick A, Phillips A, Ferro J, Karanja DMS, Mwinzi PNM, Montgomery S, Secor WE, Hamidou A, Garba A, King CH, Colley DG. Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries. *BMC Infectious Diseases*. 2016; :16.doi: 10.1186/s12879-016-1575-2 [PubMed: 26758905]
- Glenn TC, Lance SL, McKee AM, Webster BL, Emery AM, Zerlotini A, Oliveira G, Rollinson D, Faircloth BC. Significant variance in genetic diversity among populations of *Schistosoma haematobium* detected using microsatellite DNA loci from a genome-wide database. *Parasites & Vectors*. 2013; 6:300.doi: 10.1186/1756-3305-6-300 [PubMed: 24499537]
- Gower CM, Shrivastava J, Lamberton PHL, Rollinson D, Webster BL, Emery A, Kabatereine NB, Webster JP. Development and application of an ethically and epidemiologically advantageous assay for the multi-locus microsatellite analysis of *Schistosoma mansoni*. *Parasitology*. 2007; 134:523.doi: 10.1017/S0031182006001685 [PubMed: 17096873]
- Gower CM, Gabrielli AF, Sacko M, Dembelé R, Golan R, Emery AM, Rollinson D, Webster JP. Population genetics of *Schistosoma haematobium*: development of novel microsatellite markers and their application to schistosomiasis control in Mali. *Parasitology*. 2011; 138:978–994. DOI: 10.1017/S0031182011000722 [PubMed: 21679489]
- Gower CM, Gouvras AN, Lamberton PHL, Deol A, Shrivastava J, Mutombo PN, Mbuh JV, Norton AJ, Webster BL, Stothard JR, Garba A, Lamine MS, Kariuki C, Lange CN, Mkoji GM, Kabatereine NB, Gabrielli AF, Rudge JW, Fenwick A, Sacko M, Dembelé R, Lwambo NJS, Tchuem Tchuenté LA, Rollinson D, Webster JP. Population genetic structure of *Schistosoma mansoni* and *Schistosoma haematobium* from across six sub-Saharan African countries: Implications for epidemiology, evolution and control. *Acta Tropica*. 2013; 128:261–274. DOI: 10.1016/j.actatropica.2012.09.014 [PubMed: 23041540]
- Gower CM, Gehre F, Marques SR, Lamberton PHL, Lwambo NJ, Webster JP. Phenotypic and genotypic monitoring of *Schistosoma mansoni* in Tanzanian schoolchildren five years into a preventative chemotherapy national control programme. *Parasites & Vectors*. 2017; :10.doi: 10.1186/s13071-017-2533-6 [PubMed: 28061911]
- Harvey MG, Smith BT, Glenn TC, Faircloth BC, Brumfield RT. Sequence Capture versus Restriction Site Associated DNA Sequencing for Shallow Systematics. *Systematic Biology*. 2016; 65:910–924. DOI: 10.1093/sysbio/syw036 [PubMed: 27288477]
- Hotez PJ, Bundy DAP, Beegle K, Brooker S, Drake L, de Silva N, Montresor A, Engels D, Jukes M, Chitsulo L, Chow J, Laxminarayan R, Michaud C, Bethony J, Correa-Oliveira R, Shuhua X, Fenwick A, Savioli L. Helminth Infections: Soil-transmitted Helminth Infections and Schistosomiasis. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors *Disease Control Priorities in Developing Countries*. World Bank; Washington (DC): 2006.
- Lepesant JM, Cosseau C, Boissier J, Freitag M, Portela J, Climent D, Perrin C, Zerlotini A, Grunau C. Chromatin structure changes around satellite repeats on the *Schistosoma mansoni* female sex chromosome suggest a possible mechanism for sex chromosome emergence. *Genome Biology*. 2012; 13:R14.doi: 10.1186/gb-2012-13-2-r14 [PubMed: 22377319]
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009; 25:1754–1760. DOI: 10.1093/bioinformatics/btp324 [PubMed: 19451168]

- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009; 25:2078–2079. DOI: 10.1093/bioinformatics/btp352 [PubMed: 19505943]
- Li Y, Yin M, Wu Q, McManus DP, Blair D, Li H, Xu B, Mo X, Feng Z, Hu W. Genetic diversity and selection of three nuclear genes in *Schistosoma japonicum* populations. *Parasites & Vectors*. 2017; :10.doi: 10.1186/s13071-017-2033-8 [PubMed: 28061911]
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Research*. 2010; 20:1297–1303. DOI: 10.1101/gr.107524.110 [PubMed: 20644199]
- Pehlivan D, Karaca E, Aydin H, Beck CR, Gambin T, Muzny DM, Bilge Geckinli B, Karaman A, Jhangiani SN, Gibbs RA, Lupski JR. Whole-exome sequencing links TMCO1 defect syndrome with cerebro-facio-thoracic dysplasia. *European Journal of Human Genetics*. 2014; 22:1145–1148. DOI: 10.1038/ejhg.2013.291 [PubMed: 24424126]
- Protasio AV, Tsai IJ, Babbage A, Nichol S, Hunt M, Aslett MA, De Silva N, Velarde GS, Anderson TJC, Clark RC, Davidson C, Dillon GP, Holroyd NE, LoVerde PT, Lloyd C, McQuillan J, Oliveira G, Otto TD, Parker-Manuel SJ, Quail MA, Wilson RA, Zerlotini A, Dunne DW, Berriman M. A systematically improved high quality genome and transcriptome of the human blood fluke *Schistosoma mansoni*. *PLoS Negl Trop Dis*. 2012; 6:e1455.doi: 10.1371/journal.pntd.0001455 [PubMed: 22253936]
- Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010; 26:841–842. DOI: 10.1093/bioinformatics/btq033 [PubMed: 20110278]
- Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. *Journal of Human Genetics*. 2014; 59:5–15. DOI: 10.1038/jhg.2013.114 [PubMed: 24196381]
- Shaw ND, Brand H, Kupchinsky ZA, Bengani H, Plummer L, Jones TI, Erdin S, Williamson KA, Rainger J, Stortchevoi A, Samocha K, Currall BB, Dunican DS, Collins RL, Willer JR, Lek A, Lek M, Nassan M, Pereira S, Kammin T, Lucente D, Silva A, Seabra CM, Chiang C, An Y, Ansari M, Rainger JK, Joss S, Smith JC, Lippincott MF, Singh SS, Patel N, Jing JW, Law JR, Ferraro N, Verloes A, Rauch A, Steindl K, Zweier M, Scheer I, Sato D, Okamoto N, Jacobsen C, Tryggestad J, Chernausk S, Schimmenti LA, Brasseur B, Cesaretti C, Garcia-Ortiz JE, Buitrago TP, Silva OP, Hoffman JD, Mühlbauer W, Ruprecht KW, Loey BL, Shino M, Kaindl AM, Cho CH, Morton CC, Meehan RR, van Heyningen V, Liao EC, Balasubramanian R, Hall JE, Seminara SB, Macarthur D, Moore SA, Yoshiura K, Gusella JF, Marsh JA, Graham JM, Lin AE, Katsanis N, Jones PL, Crowley WF, Davis EE, FitzPatrick DR, Talkowski ME. SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome. *Nature Genetics*. 2017; 49:238–248. DOI: 10.1038/ng.3743 [PubMed: 28067909]
- Shortt JA, Card DC, Schield DR, Liu Y, Zhong B, Castoe TA, Carlton EJ, Pollock DD. Whole Genome Amplification and Reduced-Representation Genome Sequencing of *Schistosoma japonicum* Miracidia. *PLOS Neglected Tropical Diseases*. 2017; 11:e0005292.doi: 10.1371/journal.pntd.0005292 [PubMed: 28107347]
- Steinauer ML, Blouin MS, Criscione CD. Applying evolutionary genetics to schistosome epidemiology. *Infection, Genetics and Evolution*. 2010; 10:433–443. DOI: 10.1016/j.meegid.2010.02.007
- Steinauer ML, Christie MR, Blouin MS, Agola LE, Mwangi IN, Maina GM, Mutuku MW, Kinuthia JM, Mkoji GM, Loker ES. Non-Invasive Sampling of Schistosomes from Humans Requires Correcting for Family Structure. *PLoS Neglected Tropical Diseases*. 2013; 7:e2456.doi: 10.1371/journal.pntd.0002456 [PubMed: 24069499]
- Taylor AB, Roberts KM, Cao X, Clark NE, Holloway SP, Donati E, Polcaro CM, Pica-Mattoccia L, Tarpley RS, McHardy SF, Cioli D, LoVerde PT, Fitzpatrick PF, Hart PJ. Structural and enzymatic insights into species-specific resistance to schistosome parasite drug therapy. *Journal of Biological Chemistry*. 2017; 292:11154–11164. DOI: 10.1074/jbc.M116.766527 [PubMed: 28536265]
- Valentim CLL, LoVerde PT, Anderson TJC, Criscione CD. Efficient genotyping of *Schistosoma mansoni* miracidia following whole genome amplification. *Molecular and Biochemical Parasitology*. 2009; 166:81–84. DOI: 10.1016/j.molbiopara.2009.02.010 [PubMed: 19428677]




Figure 1. Workflow summarizing the protocol used to generate and analyse genomic data starting with field collecting miracidium.




Figure 2. Distribution of the number of α -tubulin copy among all the WGA schistosome samples tested

Log₁₀ distribution of the number of α -tubulin copy in 20 ng of total DNA, among the 60 East African (Tanzania) and the 37 West African (Senegal and Niger) *S. mansoni* samples, and the 65 East African (Zanzibar) and 55 West African (Niger) *S. haematobium* samples from FTA-preserved samples. *S. mansoni* and *S. haematobium* DNA varies in concentration by three to five orders of magnitude within WGA products. The 11 outliers, below the dotted line threshold, exhibited a very low number of α -tubulin copies (less than 100 copies in 20 ng of total DNA) and were removed from the next generation sequencing sample set.




Figure 3. Read depth of the bait regions for *S. mansoni* and *S. haematobium* single miracidium libraries

S. mansoni (Sm) plots show read depth of bait regions on the assembled chromosomes (grey), on unplaced scaffolds that have been assigned to chromosomes or unassigned scaffolds (black). *S. haematobium* (Sh) plots show read depth of the concatenated bait regions (bp: base pair).

Table 1

Whole genome amplification and qPCR assay summary statistics

Summary of the number and percentage of positive schistosomiasis samples, the number of patients from which schistosomiasis positive WGA were obtained, the average number of spots tested per patients in order to get at least one positive for schistosomiasis, and the average (+ sd) DNA concentration recovered after WGA in ng. μL^{-1} in 130 μL of sample.

Schistosome spp.	Location	Country	Collection date	No. schistosomiasis positive WGA/Total no. WGA performed	% schistosomiasis positive samples by qPCR	No. of patients with schistosomiasis positive WGA/no. of patients	Average no. of spots tested per patient*	Average (+ sd) DNA conc. after WGA (ng. μL^{-1})**
<i>S. mansoni</i>	E. Africa	Tanzania	2012	60/101	59.40%	60/64	1.68	34 \pm 5.19
	W. Africa	Senegal	2007–8	24/48	50%	23/27	2.09	28.74 \pm 5.08
		Niger	2006–7	13/28	46.42%	13/17	2.23	24.63 \pm 5.04
		Cameroon	2007	0/14	0%	0/6	-	-
<i>S. haematobium</i>	E. Africa	Zanzibar	2011	65/138	47.10%	62/80	2.22	22.45 \pm 4.65
	W. Africa	Niger	2013	55/83	66.26%	52/57	1.60	21.21 \pm 2.85

* We initially conducted WGA from a single miracidia per patient: further WGA were done only if the initial sample was schistosomiasis negative by qPCR

** Only shown for schistosomiasis positive samples

Table 2

Exome capture library statistics

The ratio Z/W is the ratio of the read depth of the Z-linked regions (between 3.5–19.5 Mb and 23.5–31 Mb) over the read depth of the rest of the Z chromosome. We considered a ratio between 0.5 and 0.75 corresponding to females, and a ratio over 0.75 to males. ND: not determined because the *S. haematobium* sexual chromosome is not identified in the current assembly.

Library	Total reads	Mapped reads	% mapped reads	Paired reads	Singletons	Duplicates	% bait regions captured	Mean (median) read depth in bait regions	Mean (median) read depth in bait regions + adjacent 250 bp	ZW Ratio	Sex
Sm.TZ_009.10.1	25798662	25419182	98	23340898	75658	778686	99.7	111.6 (50)	29.46 (11)	1.09	M
Sm.TZ_009.1.1	10584471	8990428	84	8401922	30943	472062	99.61	41.13 (30)	80.07 (17)	1.1	M
Sm.TZ_009.2.2	6322519	6285705	99	5908458	18458	108142	99.57	28.25 (22)	20.44 (9)	0.56	F
Sm.TZ_009.4.2	14336010	13867259	96	12681806	44233	398843	99.45	61.84 (29)	45.18 (11)	0.7	F
Sm.TZ_009.5.2	12072285	11756999	97	10697666	34578	270333	99.02	52.42 (24)	38.6 (9)	0.62	F
Sm.TZ_009.6.1	6001101	5932580	98	5457864	19447	94657	99.52	25.97 (20)	19.02 (8)	1.15	M
Sm.TZ_009.7.1	14570100	14433095	99	13250586	41663	245158	99.73	59.91 (45)	43 (14)	0.61	F
Sm.TZ_009.8.2	7832169	7306500	93	6876540	20661	137371	99.6	32.86 (25)	23.72 (10)	1.08	M
Sh.TZ_PEM0063.1	7029068	6464873	91	6040332	7279	179216	99.73	28.72 (22)	20.55 (9)	ND	ND
Sh.TZ_PEM0076.1	11544736	11392803	98	9696738	67595	480559	99.92	41.62 (35)	30.07 (12)	ND	ND
Sh.TZ_PEM0079.1	5557924	4998091	89	4672272	6737	127514	98.7	22.69 (14)	16.72 (6)	ND	ND
Sh.TZ_PEM0089.2	18364494	17933751	97	16683002	20437	390640	99.85	71.88 (57)	51.08 (17)	ND	ND
Sh.TZ_PEM0094.2	15443954	15214835	98	14091206	19001	317997	99.85	61.23 (52)	44.06 (17)	ND	ND
Sh.TZ_PEM0099.2	7069391	6672191	94	6292150	7106	124974	99.78	28.88 (24)	20.64 (9)	ND	ND
Sh.TZ_PEM0103.1	7958910	7809025	98	7293706	28039	487198	99.8	31.72 (26)	22.86 (10)	ND	ND
Sh.TZ_PEM0104.1	5051982	4824636	95	4079848	40950	200550	99.77	17.83 (15)	13.17 (6)	ND	ND

Table 3**Variant calling statistics**

Number of variable sites identified in the 8 exome capture libraries of *S. mansoni* and *S. haematobium*. We used conservative filtering parameters: minimum read depth of 10 and a minimum genotype quality (GQ) of 80.

Type of site	Number of sites in <i>S. mansoni</i>	Number of sites in <i>S. haematobium</i>
Variable sites before filtering	117,007	80,483
Variable sites after filtering	85,133	60,193
Biallelic sites	81,556	57,897
Multiallelic sites	443	522
Sites with insertion	1,335	933
Sites with deletion	2,038	1,072